Rationale Treatment of attention-deficit/hyperactivity disorder (ADHD) has for many years
relied on psychostimulants, particularly various formulations of amphetamines and …

Objectives. Atomoxetine seems to be as effective for treating attention-deficit/hyperactivity
disorder (ADHD) when the daily dose is administered once in the morning as when the dose is …

This study examined the detailed time course of desire to smoke self-reports during brief
periods of tobacco smoking deprivation to determine how these reports are related to amount …

Buprenorphine, a partial mu opioid agonist, is an experimental medication under development
for the treatment of opioid dependence as an alternative to methadone maintenance. The …

… Qiao, Schuh, and Kelsey are full-time employees and minor shareholders of Lilly USA,
LLC. Dr. Trzepacz is a full-time employee and minor shareholder of Eli Lilly and Company. …

This study examined caffeine’s acute and withdrawal effects in moderate caffeine consumers
(mean = 379 mg/day caffeine) to compare the relative contributions each might have to …

Objective. The efficacy of atomoxetine was assessed in school-age girls with attention-deficit/hyperactivity
disorder (ADHD). Atomoxetine is a potent inhibitor of the presynaptic …

Buprenorphine is a μ opioid partial agonist being developed as a treatment for opioid
dependence. Buprenorphine, usually administered as a sublingual liquid, is now being developed …

Rationale: One therapeutic benefit of mu opioid agonist or antagonist maintenance is the
resultant attenuation of the effects of illicit opioids. It is important to characterize the …

Introduction: Nocturnal enuresis is a condition in which children at least 5 years of age are
incontinent of urine at night. Atomoxetine, a potent inhibitor of the presynaptic norepinephrine …